The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

Eisai Co., Ltd.

Overview

Patients who fit the inclusion criteria are admitted into the study. They are given 3 IV injection of MBL in the first week and one tablet three times a day for 16 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Dementia With Vitamin B12 Deficiency

Interventions

MecobalaminDRUG

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion: * Patients with Dementia * Serum B12 \< 200 pmol/l * Serum Homocysteine level \> 11.0 micro mol/L Exclusion: Significant communication problems * deafness, dysarthria, dysphasia etc. * unstable DM or hypertension * alcohol abuse * co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure * folate \< 10 g/dl * haemoglobin concentration \< 10g/d * abnormal thyroid function test or VDRL

Locations (1)

Chinese University of Hong Kong

Hong Kong, Hong Kong, China

Outcomes

Primary Outcomes

Mattis dementia rating scale

Secondary Outcomes

Category fluency test

Delirium rating scale

CNPI

MMSE

Plasma homocysteine

Plasma isoprostane

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.